AlphAIAlphAI — Financial news for AI agents
investing.comSEP 251 min read$NKTR

Nektar Therapeutics stock rises on $90M jury verdict vs Lilly

Nektar Therapeutics (NKTR) shares rose 3.6% premarket after a jury awarded $90M in damages in a contract dispute with Eli Lilly (LLY). The jury found Lilly breached a license agreement. The verdict is subject to post-trial proceedings and possible appeal.

Original reporting
investing.com
Published Sep 25, 2026, 1:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$NKTR
Bullish
high confidence
Mentioned
$NKTR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NKTRBullishHigh
01

Why it matters

The verdict provides a fresh, material catalyst that has already moved NKTR's price.

02

Market read

NKTR's stock reacts positively to the legal win; traders may consider short‑term positions.

03

What to watch

Potential delay in judgment payment and impact on Lilly's stock not addressed.

Relevance 7/10Novelty 8/10Timing: premarket today

Background

NKTR sued Lilly over a license agreement; jury found Lilly breached implied covenant of good faith.

Company-level read

Ticker impact

$NKTRBullishHigh confidence
Context

Jury awarded Nektar Therapeutics $90M in a breach of contract verdict against Eli Lilly, driving a 3.6% pre‑market price rise.

Expected impact

Expect modest intraday rally; potential continuation if appeal upheld.

Evidence & confidence

The $90M verdict is a fresh, material catalyst; market reaction already shows a 3.6% rise.

Market effects

Sector

Legal win may boost sentiment in biotech licensing and partnership space.

Regional

Limited to U.S. biotech equities; no broader regional effect.

Global

Minor; primarily affects NKTR and peers monitoring contract risk.

Counterpoint

What could challenge this read

If the verdict is appealed and reversed, the rally could quickly unwind.

Key entities

  • Company
    Nektar Therapeutics

    Biopharma company receiving $90M verdict.

  • Company
    Eli Lilly and Company

    Defendant in the contract dispute.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 25
$NKTRHigh

Why is Nektar Therapeutics stock climbing today?

Nektar Therapeutics (NKTR) stock rose 1.5% after a jury awarded it $90M in a case against Eli Lilly (LLY). The verdict is subject to appeals. Wedbush cut NKTR's price target to $50, citing cautious revenue views. NKTR is in a quiet period ahead of a clinical data readout. The company has $1B in cash and investments.

investing.com2 min
SEP 25
$NKTRMed

Nektar Therapeutics Wins $90M Lilly Verdict

A jury awarded Nektar Therapeutics $90M in damages after finding Eli Lilly breached a license agreement. Nektar said the verdict is subject to post-trial proceedings and appeals. The dispute involves a collaboration for developing rezpegaldesleukin. Nektar Therapeutics (NASDAQ:NKTR) and Eli Lilly (NYSE:LLY) are involved.

grafa.com2 min
SEP 25
$NKTRMedAI 8/10

NEKTAR THERAPEUTICS (NKTR): Other Events

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach of contract and bre

SEC EDGAR 8-K1 min
AUG 31
$NKTRLow

Rezpegaldesleukin Shows Promise in Atopic Dermatitis

Rezpegaldesleukin, a drug developed by Nektar Therapeutics, significantly reduced disease severity in moderate-to-severe atopic dermatitis patients in a phase 2b trial. All doses showed improved EASI scores and secondary endpoints compared to placebo. The treatment increased regulatory T cells and reduced key AD biomarkers, with common side effects including injection-site reactions. The study was funded by Nektar Therapeutics, and some authors have financial ties to the company.

medscape.com2 min